Novo Nordisk A/S
NVOToday
-1.78%
5 Days
-7.64%
1 Month
-22.60%
6 Months
-32.38%
Year to Date
-46.90%
1 Year
-57.56%
TradingKey Stock Score of Novo Nordisk A/S
Currency: USD Updated: 2025-11-07Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novo Nordisk A/S's Score
Support & Resistance
Score Analysis
Analyst Rating
Novo Nordisk A/S Highlights
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Novo Nordisk A/S News
“Trump’s Pharmacy” Cutting Weight-Loss Drug Prices — What This Means for Novo and Lilly
TradingKey - Following agreements with Pfizer and AstraZeneca, the so-called “twin giants” of weight-loss drugs — Novo Nordisk and Eli Lilly — have now also reached pricing deals with the Trump administration. This marks the latest move in Trump’s broader push to cut U.S. drug prices by up to 90%
Novo Nordisk, Lilly strike deal with Trump to slash weight-loss drug prices
WASHINGTON, Nov 6 (Reuters) - U.S. President Donald Trump, Eli Lilly LLY.N and Novo Nordisk NOVOb.CO unveiled a deal on Thursday to slash the prices of popular GLP-1 weight‑loss drugs for the government's Medicare and Medicaid programs, as well as for cash payers.
Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly
COPENHAGEN, Nov 5 (Reuters) - Wegovy-maker Novo Nordisk NOVOb.CO trimmed its full-year forecasts on Wednesday as sales growth of its blockbuster obesity drugs slows, leaving investors worried the firm is losing ground to U.S. peer Eli Lilly LLY.N and copycat rivals.
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, source says
Nov 4 (Reuters) - Eli Lilly LLY.N and Novo Nordisk NOVOb.CO are expected to announce deals with the Trump administration to cut prices of their weight-loss drugs in exchange for Medicare coverage, a White House source told Reuters on Tuesday.Patients in the U.S. currently pay the most for prescripti
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.
Novo Nordisk fights to keep Medicaid paying for weight-loss drugs
Oct 21 (Reuters) - Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs, according to state documents, company emails and interviews with lawmakers and advocates.
Financial Indicators
EPS
Total revenue
Novo Nordisk A/S Info
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Related Instruments
Popular Symbols
